JP5055136B2 - Ｖｅｇｆ−ｒ２阻害剤としてのイミダゾ（１，２−ａ）ピリジン化合物 - Google Patents

Ｖｅｇｆ−ｒ２阻害剤としてのイミダゾ（１，２−ａ）ピリジン化合物 Download PDF

Info

Publication number: JP5055136B2
Authority: JP; Japan
Prior art keywords: mmol; pyridin; phenyl; group; imidazo
Prior art date: 2005-02-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2007557126A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008531574A5 (es

JP2008531574A (ja

Inventor

デイビッド・アンソニー・バーダ

ティモシー・ポール・バークホルダー

ジョシュア・ライアン・クレイトン

ヤン・ハオ

ペリー・クラーク・ヒース

ジェイムズ・ロバート・ヘンリー

ジョン・モント・ノーベロッチ

デイビッド・メンデル

ジョナサン・アレキサンダー・マクリーン

デイビッド・マイケル・レミック

マーク・エドワード・レンパラ

チャオ−キン・ワン

イップ・イボンヌ・イー・マイ

チョン・ボユ

Original Assignee

イーライリリーアンドカンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-24

Filing date

2006-02-23

Publication date

2012-10-24

2006-02-23 Application filed by イーライリリーアンドカンパニー filed Critical イーライリリーアンドカンパニー

2008-08-14 Publication of JP2008531574A publication Critical patent/JP2008531574A/ja

2009-04-02 Publication of JP2008531574A5 publication Critical patent/JP2008531574A5/ja

2012-10-24 Application granted granted Critical

2012-10-24 Publication of JP5055136B2 publication Critical patent/JP5055136B2/ja

Status Expired - Fee Related legal-status Critical Current

2026-02-23 Anticipated expiration legal-status Critical

Links

FLGOGCICOSENEH-XYGWBWBKSA-N CC(C)(C)/C(/O)=C/C(NC(Nc(cc1)ccc1-c1cnc2[n]1ccc(-c1cnc(N3CCN(C)CC3)nc1)c2)=O)=N Chemical compound CC(C)(C)/C(/O)=C/C(NC(Nc(cc1)ccc1-c1cnc2[n]1ccc(-c1cnc(N3CCN(C)CC3)nc1)c2)=O)=N FLGOGCICOSENEH-XYGWBWBKSA-N 0.000 description 1
UGIWAEJKHMCGLS-UHFFFAOYSA-N CC(C)(C)c1c(CN2CCOCC2)nc(NC(Cc(ccc(-c2cnc3[n]2ccc(-c2ccncc2)c3)c2)c2F)=O)[s]1 Chemical compound CC(C)(C)c1c(CN2CCOCC2)nc(NC(Cc(ccc(-c2cnc3[n]2ccc(-c2ccncc2)c3)c2)c2F)=O)[s]1 UGIWAEJKHMCGLS-UHFFFAOYSA-N 0.000 description 1
BRLKVJYFRGFTJB-UHFFFAOYSA-N CC(C)(C)c1cccc(NC(Nc(cc2)ccc2-c2cnc3[n]2ccc(-c2ccncc2)c3)=O)c1 Chemical compound CC(C)(C)c1cccc(NC(Nc(cc2)ccc2-c2cnc3[n]2ccc(-c2ccncc2)c3)=O)c1 BRLKVJYFRGFTJB-UHFFFAOYSA-N 0.000 description 1
SNTRBXUCDVHXOH-UHFFFAOYSA-N CC(C)(C)c1nnc(NC(Cc(ccc(-c2cnc3[n]2ccc(-c2ccncc2)c3)c2)c2F)=O)[s]1 Chemical compound CC(C)(C)c1nnc(NC(Cc(ccc(-c2cnc3[n]2ccc(-c2ccncc2)c3)c2)c2F)=O)[s]1 SNTRBXUCDVHXOH-UHFFFAOYSA-N 0.000 description 1
JUORUVKJAINTFQ-UHFFFAOYSA-N CC(c1cnc(NC(Cc(c(F)c2)ccc2-c2cnc3[n]2ccc(-c2ccncc2)c3)=O)[s]1)=C Chemical compound CC(c1cnc(NC(Cc(c(F)c2)ccc2-c2cnc3[n]2ccc(-c2ccncc2)c3)=O)[s]1)=C JUORUVKJAINTFQ-UHFFFAOYSA-N 0.000 description 1
YIXKKWIWQSEKEF-UHFFFAOYSA-N CCN(CC)CCS(c(cc1)ccc1-c1cc2ncc(-c3ccc(CC(Nc4n[o]c(C(C)(C)C)c4)=O)cc3)[n]2cc1)(=O)=O Chemical compound CCN(CC)CCS(c(cc1)ccc1-c1cc2ncc(-c3ccc(CC(Nc4n[o]c(C(C)(C)C)c4)=O)cc3)[n]2cc1)(=O)=O YIXKKWIWQSEKEF-UHFFFAOYSA-N 0.000 description 1
SYASEZVSSNPROS-UHFFFAOYSA-N CSc(cc1)ccc1-c1cc2ncc(-c3ccc(CNC(Cc4cccc(C(F)(F)F)c4)=O)cc3)[n]2cc1 Chemical compound CSc(cc1)ccc1-c1cc2ncc(-c3ccc(CNC(Cc4cccc(C(F)(F)F)c4)=O)cc3)[n]2cc1 SYASEZVSSNPROS-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

JP2007557126A 2005-02-24 2006-02-23 Ｖｅｇｆ−ｒ２阻害剤としてのイミダゾ（１，２−ａ）ピリジン化合物 Expired - Fee Related JP5055136B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65598105P	2005-02-24	2005-02-24
US60/655,981		2005-02-24
PCT/US2006/006283 WO2006091671A1 (en)	2005-02-24	2006-02-23	Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (3)

Publication Number	Publication Date
JP2008531574A JP2008531574A (ja)	2008-08-14
JP2008531574A5 JP2008531574A5 (es)	2009-04-02
JP5055136B2 true JP5055136B2 (ja)	2012-10-24

Family

ID=36587138

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2007557126A Expired - Fee Related JP5055136B2 (ja)	2005-02-24	2006-02-23	Ｖｅｇｆ−ｒ２阻害剤としてのイミダゾ（１，２−ａ）ピリジン化合物

Country Status (34)

Country	Link
US (1)	US7666879B2 (es)
EP (1)	EP1904494B1 (es)
JP (1)	JP5055136B2 (es)
KR (1)	KR100904938B1 (es)
CN (1)	CN101128461B (es)
AR (1)	AR056186A1 (es)
AT (1)	ATE490254T1 (es)
AU (1)	AU2006216710B2 (es)
BR (1)	BRPI0609047A2 (es)
CA (1)	CA2599124C (es)
CR (1)	CR9331A (es)
CY (1)	CY1111154T1 (es)
DE (1)	DE602006018615D1 (es)
DK (1)	DK1904494T3 (es)
DO (1)	DOP2006000051A (es)
EA (1)	EA011691B1 (es)
ES (1)	ES2354716T3 (es)
HK (1)	HK1118284A1 (es)
HR (1)	HRP20100677T1 (es)
IL (1)	IL184717A (es)
MA (1)	MA29433B1 (es)
MX (1)	MX2007010326A (es)
NO (1)	NO20074666L (es)
NZ (2)	NZ560402A (es)
PE (1)	PE20061098A1 (es)
PL (1)	PL1904494T3 (es)
PT (1)	PT1904494E (es)
RS (1)	RS51590B (es)
SI (1)	SI1904494T1 (es)
TN (1)	TNSN07323A1 (es)
TW (1)	TW200640924A (es)
UA (1)	UA91535C2 (es)
WO (1)	WO2006091671A1 (es)
ZA (1)	ZA200707136B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8895745B2 (en) *	2006-12-22	2014-11-25	Astex Therapeutics Limited	Bicyclic heterocyclic compounds as FGFR inhibitors
JP5442449B2 (ja) *	2006-12-22	2014-03-12	アステックス、セラピューティックス、リミテッド	新規化合物
US8131527B1 (en)	2006-12-22	2012-03-06	Astex Therapeutics Ltd.	FGFR pharmacophore compounds
CN101669030B (zh)	2007-03-08	2016-01-13	小利兰·斯坦福大学托管委员会	线粒体醛脱氢酶2调节剂和其使用方法
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
CA2703037A1 (en) *	2007-10-17	2009-04-23	Novartis Ag	Organic compounds
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
JP2012502048A (ja)	2008-09-08	2012-01-26	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
US8389522B2 (en)	2008-10-28	2013-03-05	The Board Of Trustees Of The Leland Stanford Junior University	Modulators of aldehyde dehydrogenase and methods of use thereof
JO3265B1 (ar)	2008-12-09	2018-09-16	Novartis Ag	مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en)	2009-04-08	2012-10-02	Boehringer Ingelheim International Gmbh	Substituted piperidines as CCR3 antagonists
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
TW201124391A (en)	2009-10-20	2011-07-16	Lundbeck & Co As H	2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en)	2010-06-10	2010-07-21	Pulmagen Therapeutics Inflamma	Kinase inhibitors
UA109290C2 (uk)	2010-10-07	2015-08-10		Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en)	2011-04-29	2019-10-29	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) *	2012-04-02	2014-11-19	Boehringer Ingelheim Int	Proceso para la produccion de inhibidores de crr
US10213421B2 (en)	2012-04-04	2019-02-26	Alkahest, Inc.	Pharmaceutical formulations comprising CCR3 antagonists
US9738636B2 (en)	2012-09-28	2017-08-22	Vanderbilt University	Fused heterocyclic compounds as selective BMP inhibitors
KR101735975B1 (ko) *	2012-11-29	2017-05-15	에프. 호프만-라 로슈 아게	이미다조피리딘 유도체
JP6410790B2 (ja)	2013-03-14	2018-10-24	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
AU2014365823B2 (en)	2013-12-16	2019-05-02	Abs Development 1, Inc.	P2X3 and/or P2X2/3 compounds and methods
CN103772308B (zh) *	2013-12-31	2015-11-18	北京颖泰嘉和生物科技股份有限公司	5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
US9988371B2 (en)	2014-06-03	2018-06-05	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Benzimidazole analogues and related methods
KR102485100B1 (ko)	2014-07-17	2023-01-04	선샤인 레이크 파르마 컴퍼니 리미티드	치환된 우레아 유도체 및 이의 약제학적 용도
CN104163790B (zh) *	2014-08-19	2016-02-10	贵州威顿晶磷电子材料股份有限公司	一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en)	2015-07-28	2020-11-10	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
JP2018526452A (ja) *	2015-09-03	2018-09-13	アリゾナボードオブリージェンツオンビハーフオブザユニバーシティーオブアリゾナ	Ｄｙｒｋ１ａの小分子抑制剤およびその使用
WO2017161045A1 (en) *	2016-03-16	2017-09-21	Plexxikon Inc.	Compounds and methods for kinase modulation and indications therefore
WO2019178383A1 (en)	2018-03-14	2019-09-19	Vanderbilt University	Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en)	2018-06-18	2019-03-26	Avista Pharma Solutions, Inc.	Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
MX2021007925A (es)	2018-12-31	2021-10-26	Biomea Fusion Llc	Inhibidores irreversibles de la interaccion menina-mll.
EP3906029A4 (en)	2018-12-31	2022-09-21	Biomea Fusion, LLC	INHIBITORS OF MENIN-MLL INTERACTION
MX2021009251A (es) *	2019-01-30	2021-09-21	Avista Pharma Solutions Inc	Proceso de sintesis y nuevos compuestos intermedios.
EP3917932A4 (en)	2019-01-30	2022-09-28	Avista Pharma Solutions, Inc.	CHEMICAL COMPOUNDS
US20220098204A1 (en) *	2019-02-18	2022-03-31	Shenzhen Targetrx, Inc.	Substituted fused aromatic ring derivative, composition and use thereof
CN114466847A (zh) *	2019-06-25	2022-05-10	西诺普塞疗法公司	用于治疗癌症的化合物
CN112778294A (zh) *	2021-01-07	2021-05-11	苏州安睿药业有限公司	5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0888310B1 (en)	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine
EP1017682A4 (en)	1997-09-26	2000-11-08	Merck & Co Inc	NEW ANGIOGENESIS INHIBITORS
ES2253233T3 (es)	1999-07-09	2006-06-01	Boehringer Ingelheim Pharmaceuticals Inc.	Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6492529B1 (en) *	2000-01-18	2002-12-10	Boehringer Ingelheim Pharmaceuticals, Inc.	Bis pyrazole-1H-pyrazole intermediates and their synthesis
US6916814B2 (en)	2001-07-11	2005-07-12	Boehringer Ingelheim Pharmaceuticals, Inc.	Methods of treating cytokine mediated diseases
JP2003313126A (ja) *	2002-04-23	2003-11-06	Sankyo Co Ltd	イミダゾピリジン誘導体を有効成分とする医薬
CA2483084A1 (en) *	2002-05-02	2003-11-13	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2004052315A2 (en) *	2002-12-11	2004-06-24	Merck & Co., Inc.	Tyrosine kinase inhibitors
AU2003298942A1 (en) *	2002-12-11	2004-06-30	Merck And Co., Inc.	Tyrosine kinase inhibitors
CA2535416A1 (en)	2003-08-15	2005-02-24	Banyu Pharmaceutical Co., Ltd.	Imidazopyridine derivatives

2006
- 2006-02-22 DO DO2006000051A patent/DOP2006000051A/es unknown
- 2006-02-23 EP EP06735794A patent/EP1904494B1/en active Active
- 2006-02-23 ES ES06735794T patent/ES2354716T3/es active Active
- 2006-02-23 RS RS20110042A patent/RS51590B/en unknown
- 2006-02-23 TW TW095106022A patent/TW200640924A/zh unknown
- 2006-02-23 AR ARP060100668A patent/AR056186A1/es not_active Application Discontinuation
- 2006-02-23 DK DK06735794.7T patent/DK1904494T3/da active
- 2006-02-23 PL PL06735794T patent/PL1904494T3/pl unknown
- 2006-02-23 DE DE602006018615T patent/DE602006018615D1/de active Active
- 2006-02-23 EA EA200701802A patent/EA011691B1/ru not_active IP Right Cessation
- 2006-02-23 CN CN2006800060044A patent/CN101128461B/zh not_active Expired - Fee Related
- 2006-02-23 AU AU2006216710A patent/AU2006216710B2/en not_active Ceased
- 2006-02-23 US US11/816,416 patent/US7666879B2/en not_active Expired - Fee Related
- 2006-02-23 PT PT06735794T patent/PT1904494E/pt unknown
- 2006-02-23 MX MX2007010326A patent/MX2007010326A/es active IP Right Grant
- 2006-02-23 NZ NZ560402A patent/NZ560402A/en not_active IP Right Cessation
- 2006-02-23 BR BRPI0609047-8A patent/BRPI0609047A2/pt not_active IP Right Cessation
- 2006-02-23 JP JP2007557126A patent/JP5055136B2/ja not_active Expired - Fee Related
- 2006-02-23 PE PE2006000219A patent/PE20061098A1/es not_active Application Discontinuation
- 2006-02-23 KR KR1020077019338A patent/KR100904938B1/ko not_active IP Right Cessation
- 2006-02-23 UA UAA200709559A patent/UA91535C2/ru unknown
- 2006-02-23 AT AT06735794T patent/ATE490254T1/de active
- 2006-02-23 WO PCT/US2006/006283 patent/WO2006091671A1/en active Application Filing
- 2006-02-23 CA CA2599124A patent/CA2599124C/en not_active Expired - Fee Related
- 2006-02-23 SI SI200630871T patent/SI1904494T1/sl unknown
- 2006-02-23 NZ NZ584753A patent/NZ584753A/en not_active IP Right Cessation
2007
- 2007-07-19 IL IL184717A patent/IL184717A/en not_active IP Right Cessation
- 2007-08-22 CR CR9331A patent/CR9331A/es not_active Application Discontinuation
- 2007-08-23 ZA ZA200707136A patent/ZA200707136B/xx unknown
- 2007-08-23 TN TNP2007000323A patent/TNSN07323A1/en unknown
- 2007-09-13 NO NO20074666A patent/NO20074666L/no not_active Application Discontinuation
- 2007-09-24 MA MA30233A patent/MA29433B1/fr unknown
2008
- 2008-08-25 HK HK08109446.3A patent/HK1118284A1/xx not_active IP Right Cessation
2010
- 2010-12-07 HR HR20100677T patent/HRP20100677T1/hr unknown
2011
- 2011-02-03 CY CY20111100115T patent/CY1111154T1/el unknown

Also Published As

Publication number	Publication date
MA29433B1 (fr)	2008-05-02
IL184717A (en)	2011-11-30
MX2007010326A (es)	2007-10-16
EP1904494A1 (en)	2008-04-02
CY1111154T1 (el)	2015-06-11
AR056186A1 (es)	2007-09-26
SI1904494T1 (sl)	2011-02-28
CN101128461B (zh)	2010-12-22
US20090227622A1 (en)	2009-09-10
HK1118284A1 (en)	2009-02-06
EA011691B1 (ru)	2009-04-28
NO20074666L (no)	2007-11-09
BRPI0609047A2 (pt)	2010-11-16
KR100904938B1 (ko)	2009-06-29
PE20061098A1 (es)	2006-10-20
NZ584753A (en)	2011-06-30
TNSN07323A1 (en)	2008-12-31
CA2599124A1 (en)	2006-08-31
EA200701802A1 (ru)	2008-02-28
CN101128461A (zh)	2008-02-20
HRP20100677T1 (hr)	2011-01-31
KR20070099029A (ko)	2007-10-08
EP1904494B1 (en)	2010-12-01
AU2006216710A1 (en)	2006-08-31
DOP2006000051A (es)	2006-08-31
TW200640924A (en)	2006-12-01
ZA200707136B (en)	2008-11-26
ES2354716T3 (es)	2011-03-17
IL184717A0 (en)	2007-12-03
WO2006091671A1 (en)	2006-08-31
PL1904494T3 (pl)	2011-04-29
US7666879B2 (en)	2010-02-23
CR9331A (es)	2008-03-31
AU2006216710B2 (en)	2011-08-11
ATE490254T1 (de)	2010-12-15
UA91535C2 (en)	2010-08-10
DK1904494T3 (da)	2011-02-21
JP2008531574A (ja)	2008-08-14
RS51590B (en)	2011-08-31
PT1904494E (pt)	2010-12-23
NZ560402A (en)	2010-06-25
CA2599124C (en)	2013-08-06
DE602006018615D1 (de)	2011-01-13

Legal Events

Date	Code	Title	Description
2009-02-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090216
2009-02-17	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090216
2011-10-27	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111026
2011-11-09	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111108
2012-02-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120206
2012-04-04	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120403
2012-06-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120614
2012-07-13	TRDD	Decision of grant or rejection written
2012-07-25	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120724
2012-07-26	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-08-02	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120730
2012-08-03	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-08-06	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150803 Year of fee payment: 3
2015-08-03	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP5055136B2 (ja)	2012-10-24	Ｖｅｇｆ−ｒ２阻害剤としてのイミダゾ（１，２−ａ）ピリジン化合物
JP6224095B2 (ja)	2017-11-01	ピリジノンおよびピリダジノン誘導体
JP6545199B2 (ja)	2019-07-17	３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類
RU2482112C2 (ru)	2013-05-20	Ингибиторы киназ, применимые для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
US8916593B2 (en)	2014-12-23	Alkoxy-substituted 2-aminopyridines as ALK inhibitors
KR101544624B1 (ko)	2015-08-17	피리미디닐 피리다지논 유도체
JP5255438B2 (ja)	2013-08-07	プロテインキナーゼ阻害薬として有用なベンズイミダゾール
JP5406030B2 (ja)	2014-02-05	複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用
CA2890929A1 (en)	2014-05-15	Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
US20140148453A1 (en)	2014-05-29	Sulfonamide compounds useful as cyp17 inhibitors
US10703748B2 (en)	2020-07-07	Diazanaphthalen-3-yl carboxamides and preparation and use thereof
US9475817B2 (en)	2016-10-25	Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
CA3174845A1 (en)	2021-10-21	Substituted pyridines for the treatment of inflammatory diseases
US20220298168A1 (en)	2022-09-22	Compounds and uses thereof
US20230078764A1 (en)	2023-03-16	Compounds and uses thereof